SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Access with Evidence Development Schemes
3 references·1 citing·20 second hop
Access with Evidence Development Schemes (2010)Access with Evidence Development SchemesFunding the Unfundable (2010)Funding the UnfundableExploring Uncertainty in Cost-Effectiveness Analysis (2008)Exploring Uncertainty in Cost…Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis (2003)Modelling the cost effectiven…USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT” (2012)USING HEALTH TECHNOLOGY ASSES…Probabilistic Sensitivity Analysis Using Monte Carlo Simulation (1985)Time Preference (1996)Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis (2007)Cost-effectiveness of disease-modifying therapy for multiple sclerosis (2011)Systematic Reviews in Health Care : Meta-Analysis in Context (2000)Site-ation pearl growing: methods and librarianship history and theory. (2005)Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’ (2006)Health Technology Funding Decision-Making Processes Around the World (2011)Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries (2013)Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review (2015)Prospect theory: An analysis of decision under risk (1988)Prospect Theory: An Analysis of Decision under Risk (2000)BEST PRACTICE IN UNDERTAKING AND REPORTING HEALTH TECHNOLOGY ASSESSMENTS (2002)HTA Implementation Roadmap in Central and Eastern European Countries (2016)Net Health Benefits (1998)Representing uncertainty: the role of cost‐effectiveness acceptability curves (2001)Uncertain Judgements: Eliciting Experts' Probabilities (2006)Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models (2011)Cost-effectiveness analyses of genetic and genomic diagnostic tests (2018)Calculating and Interpreting ICERs and Net Benefit (2020)
this work references cited by second hop

References

  • 2008Exploring Uncertainty in Cost-Effectiveness Analysis210 cited
  • 2003Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis142 cited
  • 2010Funding the Unfundable132 cited

Cited by

  • 2012USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT”82 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work